NZ534939A - Injectable formulation comprising an anthelmintic compound with complexing compound for improved solubility - Google Patents

Injectable formulation comprising an anthelmintic compound with complexing compound for improved solubility

Info

Publication number
NZ534939A
NZ534939A NZ534939A NZ53493904A NZ534939A NZ 534939 A NZ534939 A NZ 534939A NZ 534939 A NZ534939 A NZ 534939A NZ 53493904 A NZ53493904 A NZ 53493904A NZ 534939 A NZ534939 A NZ 534939A
Authority
NZ
New Zealand
Prior art keywords
formulation
compound
benzimidazole compound
injectable formulation
cyclodextrin
Prior art date
Application number
NZ534939A
Inventor
Natalie Medlicot
Majid Razzak
Ian George Tucker
Zimei Wu
Original Assignee
Bomac Research Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bomac Research Ltd filed Critical Bomac Research Ltd
Priority to NZ534939A priority Critical patent/NZ534939A/en
Priority to PCT/NZ2005/000225 priority patent/WO2006022562A1/en
Publication of NZ534939A publication Critical patent/NZ534939A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/724—Cyclodextrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nanotechnology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Disclosed is an injectable formulation and method of increasing the solubility and/or dispersion characteristics of a benzimidazole compound of the general formula I which is complexed with a cyclodextrin compound selected from: (a) hydroxypropyl beta-cyclodextrin compounds of formula (a) where R is CH2CHOHCH3 or H; or, (b) sulphabutyl ether beta-cyclodextrin compounds with the formula (b) where R is (CH2)4SO3Na or H; or, (c) alpha-cyclodextrin with six sugar units in the cyclodextrin ring; or, (d) gamma-cyclodextrin with eight sugar units in the cyclodextrin ring; and mixed with benzyl alcohol. The formulation is characterised by the increased solubility and/or dispersion properties of the benzimidazole compound and used in the manufacture of medicaments for the treatment of parasite infections in animals.

Description

PATENTS FORM NO. 5 Fee No. 4: $250.00 PATENTS ACT 1953 COMPLETE SPECIFICATION After Provisional No: 534939 Dated: 26 August 2004 IMPROVED CHEMICAL DELIVERY FORMULATIONS We, Bomac Research Limited, a New Zealand company of 102 Wiri Station Road & Hobill Avenue, Manukau City, Auckland, NEW ZEALAND hereby declare the invention for which we pray that a patent may be granted to us, and the method by which it is to be performed to be particularly described in and by the following statement: IMPROVED CHEMICAL DELIVERY FORMULATIONS TECHNICAL FIELD The invention relates to improved chemical delivery formulations. In particular, the invention relates to formulations that more readily solubilise and/or disperse poorly soluble chemical compounds and related methods for improving solubility and/or dispersion. More specifically, the invention relates to formulations containing poorly soluble anthelmintic chemical compounds that are formulated so as to increase the solubility and/or dispersion characteristics of the anthelmintic compound. Related methods are also described pertaining to the formulation properties and uses.
BACKGROUND ART Drug delivery formulations are well known in the art and include vehicles, excipients, fillers, solvents, and a wide variety of other substances to enable compounds such as pharmaceutical drugs to be administered to patients (human and animal).
A preferred administration pathway for many drugs is by injection. Injections are favourable as: • They are typically fast acting as the drug is delivered direct to the site or directly into the blood stream; • They often require less active agent (and therefore less cost and/or side effects) as there are minimal losses associated with other pathways such as digestion; and, • Food effects on drug bioavailability are avoided • "First-pass" metabolism is avoided Anthelmintic chemical compounds are widely known agents that are destructive to worms and used for removing internal parasitic worms in animals including humans.
There are many different types of anthelmintic compound, each with varying degrees of parasitic activity and chemical properties. One characteristic of many anthelmintic compounds is that they are poorly soluble in aqueous environments such as within animal tissue. A current method of addressing this problem is to use a variety of formulation compounds to assist in dispersion. Such compounds can markedly increase the cost of a drug and/or may introduce other undesirable effects such as side effects on administration and more complicated administration procedures.
Benzimidazole compounds are one family of anthelmintic compounds having a general 2 structure of: H Benzimidazole compounds in particular are sparingly soluble in aqueous environments. Benzimidazole compounds are a ring system including a benzene ring fused with an imidazole ring. Imidazole is a five membered heterocyclic compound present in various biologically important compounds. Benzimidazole compounds exist in nature as part of the vitamin B12 molecule.
A derivative of benzimidazole is albendazole with the structure: H o H Albendazole is a known broad spectrum anthelmintic effective against many parasites.
Ricobendazole is a benzimidazole anthelmintic, which is an active metabolite generated by oxidation of albendazole, with the structure: H Ricobendazole is one of the most modern of the benzimidazoles and has confirmed activity against all major internal parasites and their eggs in at least sheep.
Other benzimidazole anthelmintics related to ricobendazole include fenbendazole with a structure of: O H oxfenbendazole with a structure of: 3 and parbendazole with a structure of: H A problem found in the prior art with existing anthelmintic compounds including benzimidazole anthelmintics, is the need to deliver the compound as an oral suspension due to the particularly poor solubility of this type of compound in aqueous environments. As discussed above, a preferred method of administration is by injection however, as the solubility of the anthelmintic is often poor, injections are not readily absorbed and often may cause pain to the animal or human patient due to inadequate absorption or precipitate formation.
Reference will now be made to ricobendazole however, this should not be seen as limiting as it should be appreciated by those skilled in the art that the properties exhibited by ricobendazole also relate to other anthelmintic compounds.
Ricobendazole is characteristic of the poor solubility properties of at least some anthelmintic compounds. Ricobendazole is only soluble in water at extremes of pH level i.e. less than pH 2 or greater than pH 11. As a consequence of the low solubility, existing formulations are normally administered orally to the animal or human.
Two injectable ricobendazole formulations known to the inventors exist that utilise a pH of less than 2 (Bayverm PI™ and Sintyotal-R™) to achieve a desired solubility. In the inventors experience however, it is estimated from pharmacokinetics that the bioavailability of these formulations is low at 37-40%. It is understood that this is because the majority of the active agent precipitates out of solution on entry into the subject's body as the acidic pH is quickly neutralised once the injection mixes with extracellular tissue fluid. The resulting precipitated active must then redissolve to be effective which either does not occur or, occurs too slowly to be effective.
A further problem noted with low pH formulations is pain, swelling and inflammation at the injection site. These reactions may also be associated with the anthelmintic compound such as a reaction from the subject against precipitated drug.
It is an object of the present invention to address the foregoing problems or at least to provide the public with a useful choice. 4 All references, including any patents or patent applications cited in this specification are hereby incorporated by reference. No admission is made that any reference constitutes prior art. The discussion of the references states what their authors assert, and the applicants reserve the right to challenge the accuracy and pertinency of the cited documents. It will be clearly understood that, although a number of prior art publications are referred to herein, this reference does not constitute an admission that any of these documents form part of the common general knowledge in the art, in New Zealand or in any other country.
It is acknowledged that the term 'comprise' may, under varying jurisdictions, be attributed with either an exclusive or an inclusive meaning. For the purpose of this specification, and unless otherwise noted, the term 'comprise' shall have an inclusive meaning - i.e. that it will be taken to mean an inclusion of not only the listed components it directly references, but also other non-specified components or elements. This rationale will also be used when the term 'comprised' or 'comprising' is used in relation to one or more steps in a method or process.
Further aspects and advantages of the present invention will become apparent from the ensuing description which is given by way of example only.
DISCLOSURE OF INVENTION The invention broadly relates to various formulations containing anthelmintic compounds poorly soluble in aqueous environments to minimise the impact of irritant compounds within the composition; improve the pharmacokinetics of the irritant compounds; and regulate the concentration of irritant compounds at the injection site.
The term 'anthelmintic compound' refers to chemical agents that are destructive to worms and typically used for removing internal parasitic worms in animals including humans.
The term 'complexed' or 'complexing' refers to anthelmintic compound being physically or chemically bound to another compound which results in an alteration in the solubility of the resulting combination.
The term 'emulsion' refers to a preparation of one liquid distributed in small globules throughout the body of a second liquid.
The term 'micro-emulsion' refers to an isotropic, thermodynamically stable mixture of oil, water and surfactants.
The term 'aqueous environment' refers to substantially liquid water environments including, but not limited to, extracellular tissue fluid.
According to one aspect of the present invention there is provided an injectable formulation including at least one anthelmintic compound which is complexed with at least one complexing compound wherein the complexing compound is characterised by its ability to alter the solubility and/or dispersion properties of the anthelmintic compound.
Preferably, the complexing compound is a p-cyclodextrin compound of the formula: ch2oh ho oh 0-af>°h o. hoch2 ho. ,ch2oh ho ph o- k_/H ch2oh ° / ho or, ch2or choor ch2or or an analogue or derivative thereof.
More preferably, the complexing compound is a cyclodextrin compound selected from: (a) hydroxypropyl p-cyclodextrin compounds of the formula: ch2or roch, IjaP" ch->or ch2or CHiOR 6 where R is CH2CHOHCH3 or H; or, (b) sulphabutyl ether p-cyclodextrin compounds with the formula: ch2or roch2 roch2 o o ch2or ch2or where R is (CH2)4S03Na or H; or, (c) a-cyclodextrin with six sugar units in the cyclodextrin ring; or, (d) y-cyclodextrin with eight sugar units in the cyclodextrin ring.
Most preferably, the complexing compound is hydroxypropyl-p-cyclodextrin with the formula: where R is CH2CHOHCH3 or H.
In preferred embodiments, the injectable formulation includes approximately 20%w/v hydroxypropyl-p-cyclodextrin.
In one embodiment, the injectable formulation also includes benzyl alcohol.
It is the inventors' experience that the injectable formulation described above releases the anthelmintic compound in a rapid manner once administered to an animal or when placed in an aqueous environment. ch2or 7 According to a further aspect of the present invention, there is provided an injectable formulation including at least one anthelmintic compound which is in the form of a micro-emulsion wherein the anthelmintic compound is characterised by having poor solubility and/or dispersion characteristics in an aqueous environment.
Preferably, the micro-emulsion formulation includes at least one medium chain triglyceride compound and at least one emulsifier. Most preferably, the micro-emulsion formulation includes 75% wt of at least one medium chain triglyceride compound and at least one emulsifier.
According to a further aspect of the present invention there is provided an injectable formulation including at least one anthelmintic compound which is in the form of a water in oil emulsion wherein the anthelmintic compound is characterised by having poor solubility and/or dispersion characteristics in an aqueous environment.
Preferably, the water in oil emulsion formulation includes ethyloleate and at least one emulsifier. Most preferably, the water in oil emulsion formulation includes 42% wt ethyloleate and 3% wt emulsifiers.
The above embodiments should not be seen as limiting, as it should be appreciated by those skilled in the art, that ranges of constituents outside of the above ranges may also be used without departing from the scope of the invention. Further, use of medium chain triglyceride, ethyloleate and emulsifiers should also not be seen as limiting, as it should be appreciated by those skilled in the art, that other pharmaceutically and physiologically acceptable compositions may also be used without departing from the scope of the invention.
It is the inventors' experience that the water in oil emulsion described above releases the anthelmintic compound in a slow manner.
In preferred embodiments, the above formulations are characterised by their ability to retain anthelmintic compounds in solution within internal aqueous droplets of the systems and as a result, alter the solubility and/or dispersion properties of the anthelmintic compound.
More preferably, the injectable formulations above are particularly advantageous where the anthelmintic compound has a solubility in an aqueous environment of less than 10mg of anthelmintic per ml of aqueous solution.
Expressed another way, the injectable formulations above are particularly advantageous where the anthelmintic compound is characterised by having a bioavailability of less than approximately 50% absorption of the anthelmintic compound in the blood stream.
Preferably, the injectable formulation the aqueous environment that the formulation is administered to is extra-cellular fluid.
Preferably, the anthelmintic compound is a benzimidazole compound of the formula: 8 I H In one embodiment, the benzimidazole compound is albendazole: H o fTVV1 11 /—N—C—O—CH, H3c-^s^^y H and combinations, analogues and derivatives thereof.
In another embodiment, the benzimidazole compound is ricobendazole: H and combinations, analogues and derivatives thereof.
In another embodiment, the benzimidazole compound is fenbendazole: and combinations, analogues and derivatives thereof.
In another embodiment, the benzimidazole compound is oxfenbendazole: and combinations, analogues and derivatives thereof.
In another embodiment, the benzimidazole compound is parbendazole: 9 H and combinations, analogues and derivatives thereof.
Preferably, the formulation is administered by means selected from: intravenous, subcutaneously, intramuscular.
Preferably, the anthelmintic compound is acidified with acid to a pH of 2 or less.
Preferably, the acid is hydrochloric acid.
According to a further aspect of the present invention there is provided a method of treating a parasite infection in an animal by administration of an injectable formulation substantially as described above.
According to a further aspect of the present invention there is provided a method of increasing the solubility and/or dispersion of an anthelmintic compound in an aqueous environment by complexing the anthelmintic compound with at least one complexing compound. Preferably, the anthelmintic compound is a benzimidazole compound and the complexing agent is a cyclodextrin compound.
According to a further aspect of the present invention there is provided a method of increasing the solubility and/or dispersion characteristics of an anthelmintic compound in an aqueous environment by mixing the anthelmintic compound into a micro-emulsion. Preferably, the micro-emulsion includes at least one medium chain triglyceride compound and at least one emulsifier.
According to a further aspect of the present invention there is provided a method of increasing the solubility and/or dispersion characteristics of an anthelmintic compound in an aqueous environment by mixing the anthelmintic compound into a water in oil emulsion. Preferably, the water in oil emulsion includes ethyloleate and at least one emulsifier.
According to a further aspect of the present invention there is provided a method of increasing the bioavailability of an anthelmintic compound wherein the anthelmintic compound is characterised by having poor solubility and/or dispersion characteristics in an aqueous environment, via any one of the steps of: (a) complexing the anthelmintic compound with at least one cyclodextrin compound; (b) mixing the anthelmintic compound into a water in oil emulsion; or, (c) mixing the anthelmintic compound into a micro-emulsion.
Preferably, the anthelmintic compound above is a benzimidazole compound.
According to a further aspect of the present invention there is provided the use of a formulation substantially as described above in the manufacture of a medicament for the treatment of a parasite infection in an animal.
According to a further aspect of the present invention there is provided the use of a formulation substantially as described above in the manufacture of a medicament to increase the solubility and/or dispersion of an anthelmintic compound wherein the anthelmintic compound is characterised by having poor solubility and/or dispersion characteristics in an aqueous environment.
It should be appreciated by those skilled in the art that in preferred embodiments the formulations, methods and uses described above may substantially address the solubility and/or dispersion and bioavailability problems of prior art formulations. They may also minimise the impact of irritant compounds within the composition; improve the pharmacokinetics of the irritant compounds; and regulate the concentration of irritant compounds at the injection site. A further advantage is that, as the bioavailability is increased, dosages of agent may be decreased.
BRIEF DESCRIPTION OF THE DRAWINGS Further aspects of the present invention will become apparent from the following description which is given by way of example only and with reference to the accompanying drawings in which: Figure 1 Figure 2 Figure 3 Figure 4 Figure 5 Figure 6 Figure 7 11 shows a graph of normal ricobendazole solubility as a function of pH level; shows a graph of ricobendazole solubility as a function of hydroxypropyl-p-cyclodextrin ('HP-P-CD') concentration; shows a graph comparing plasma creatine kinase levels in test sheep A and B tested over time; shows a graph comparing plasma creatine kinase levels in test sheep C, D and E tested over time; shows a skin section of normal tissue; shows a skin section from positive control sheep C; shows the variation in time of ricobendazole concentration in blood plasma of tested sheep; Figure 8 shows the variation in time of albendazole sulfone concentration in blood plasma of tested sheep; Figure 9 shows a schematic of a sheep back showing the location of injections sites; Figure 10 shows microscopic observations of tissue collected at the injection site. A: perivascular dermatitis; B: steatitis; C: muscle damage; D: dermal necrosis; Figure 11 shows graph illustrating the average skin temperature at the injection sites after subcutaneous injection of two ricobendazole formulations (labelled F for formulations 1 and 3) and vehicles (labelled V for formulations 2 and 4) in sheep. A: Skin temperature at the injection site and reference sites after injection of formulations 1 and 2 (n=6); B: formulations 3 and 4 (n=5); C: changes at injection sites relative to the reference sites. Data presented as mean values with standard error bars; Figure 12 shows a graph comparing changes in plasma creatine kinase after subcutaneous administration of two ricobendazole formulations (formulations 1 and 3) at 0.1 ml/kg along with the respective vehicle (formulations 2 and 4) at the opposite side of sheep back at the same dose. Data represented as the mean ± standard error; Figure 13 shows graphs comparing the plasma concentration-time profiles of ricobendazole (solid symbols) and albendazole sulfone ABZS02(open symbols) in sheep A, B, D, E, H, and I after subcutaneous administration of formulations 1 and 3; Figure 14 shows graphs comparing plasma concentration-time profiles of ricobendazole (solid symbols) and albendazole sulfone ABZS02 (open symbols) in sheep C, F, G, J, and K after subcutaneous administration of formulations 1 and 3; and, Figure 15 shows a graph illustrating mean plasma concentration-time profiles of ricobendazole (solid symbols) and albendazole sulfone ABZS02(open symbols) after subcutaneous administration in sheep of two ricobendazole containing formulations (outline triangles for formulation 3, n=5; and solid triangles for formulation 1, n=6). Data represented as the mean ± standard error.
BEST MODES FOR CARRYING OUT THE INVENTION The formulation of the present invention will now be described with reference to a series of three experiments.
Experimental Background 12 Ricobendazole is a poorly soluble anthelmintic and is used for the purposes of the experiment. This should not be seen as limiting as it should be appreciated by those skilled in the art that the formulation methods may also be applied to other poorly soluble anthelmintic compounds.
Low pH has been the preferred approach to achieve the desired solubility and bioavailability at the target dose. This is because ricobendazole has higher solubility levels in aqueous environments at extremes of pH level (see Figure 1).
Existing market products Bayverm PI™ and Sintyotal-R™ use low pH (pH = 1) solution and co-solvents to improve solubility but have been reported as causing site irritation and poor bioavailability (37% to 40%). It is understood by the inventors that this may be caused by local drug precipitation at the injection site.
To address the above problems, the inventors have developed formulations using ricobendazole compound to minimise the immediate irritation reactions resulting from existing formulations.
There are various methods to evaluate the irritation of parenteral formulations in the literature. The methods used in this experiment included: • Observation of animal response to the injection; • Visual observation of the injection sites; • Palpation of the injection site; • Skin temperature readings at injection sites; • Plasma creatine kinase levels (levels can alter due to damage of superficial muscular tissue); and • Histology examinations of the injection site of the skin.
Experiments Undertaken Experimentation was split into three key experiments. The first experiment was an in vitro characterisation trial to determine the degree of precipitation exhibited by the proposed formulations.
The second experiment was an in vivo trial using sheep to determine the effectiveness of the proposed formulations.
The third experiment was an additional in vivo trial using sheep to further determine the effectiveness of a complexed anthelmintic formulation.
[A1 Experiment 1 - In Vitro Characterisation 13 Formulation Preparation The formulations used include: 1. A water in oil emulsion; 2. A micro-emulsion formulation; and, 3. A complexed formulation using hydroxylpropyl-(3-cyclodextrin as the complexing agent.
With respect to the complexed formulation, the inventors have found that cyclodextrin improves the solubility of anthelmintics that are poorly soluble in aqueous environments. An example of the degree of solubility change observed is shown in Figure 2.
To characterise the proposed formulations, three formulations were prepared, all of which contained approximately 5%w/v ricobendazole, as follows: 1. Water-in-oil emulsion Formula for 100 ml 5%w/v ricobendazole water-in-oil emulsion injection Ingredients Ricobendazole 5 g 2 M hydrochloric acid 15 ml Water for injection 29.8 ml Ethyl oleate 42 g Benzyl alcohol 1 g Butylated hydroxytoluene (BHT) 0.02 g Sorbitan monooleate (Span 80) 1.5 g Polyglycerol polyricinoleate (PGPR) 1.5 g Method of preparation a. Preparation of aqueous phase Step 1. Dissolve ricobendazole in 2M HCI by heating up to 50-60 °C; Step 2. Add water for injection at 60 °C slowly with stirring; Step 3. Cool down to room temperature and pass the solution through a 0.2 micron filter and fill into vials. b. Preparation of oil phase 14 Dissolve BHT, PGPR and Span 80 in ethyl oleate by stirring; pass the solution through a 0.2 pm filter and fill into vials (solution may be heated so to pass filter easily). Alternatively ethyl oleate can be sterilized by heating at 150 °C for 1 hour.) c. Emulsion preparation Prior to use add aqueous phase into the oil phase, emulsifying by hand-shaking till milky emulsion formed (2 minutes). 2. Micro emulsion Formula for 100 ml 5%w/v ricobendazole micro emulsion injection Ingredients Ricobendazole 5g 2M hydrochloric acid (ml) ml Water for injection 9.5 ml Medium chain triglyceride (MCT) g Sorbitan monooleate (Span 80) g Solutol HS 15 g Labrasol® g Benzyl alcohol ig Method of preparation a. Preparation of aqueous phase Step 1. Dissolve ricobendazole in 2M HCI by heating up to 50-60 °C; Step 2. Add water for injection at 50-60 °C slowly with stirring; Step 3. Cool down to room temperature and pass the solution through a 0.2 micron filter and fill into vials. b. Preparation of oil phase Mix MCT, benzyl alcohol, Span 80, Solutol and Labrasol by stirring, pass the solution through a 0.2 p filter and fill into vials (solution may be heated so to pass filter easily). c. Micro emulsion preparation Prior to use add aqueous phase into the oil phase, emulsifying by hand-shaking till clear solution formed. 3. Cyclodextrin solution Formula for 100 ml 5%w/v ricobendazole injection Ingredients Ricobendazole 5 g 2M hydrochloric acid 15 ml Hydroxylpropyl-p-cyclodextrin 20 g Benzyl alcohol 1 ml Water for injection 100 ml Method of preparation Step 1. Dissolve ricobendazole in 2M HCI by heating up to 60 °C; Step 2. Dissolve hydroxylpropyl-p-cyclodextrin in about 50 ml water for injection; Step 3. Add solution from step 2 into solution from step 1 while stirring; Step 4. Add benzyl alcohol, make up volume with water for injection; Step 5. Pass the final solution though a 0.2 p filter and fill into vials.
Control Formulation A control formulation was also prepared being a ricobendazole hydrochloride (HCI) solution (pH<2). As shown in Figure 1, ricobendazole exhibits increased solubility at pH extremes.
Methodology The droplet size of the emulsion was determined by laser diffraction.
Drug release from the emulsion and micro-emulsion was conducted in modified Franz diffusion cells and released ricobendazole measured by UV spectroscopy.
Light microscopy was used to examine the interface between the formulations and a diluting phosphate buffer (SPB: pH 7.4, 0.08M). pH changes to SPB buffer on titration with the formulations were measured and drug precipitation from the cyclodextrin formulation was compared with the control solution by light scattering at 550nm.
Characterisation Results The water in oil emulsion formulation was found to have a mean droplet size of 2.5pm. 16 Cumulative release of ricobendazole from the emulsion and micro-emulsion was found to be proportional to the square root time (R2>0.99).
Light microscopy on dilution with SPB buffer showed formation of areas of water/oil/water emulsion at the interface between the water in oil emulsion and buffer and no evidence of droplet rupture.
For the micro-emulsion an emulsion layer appeared at the interface.
No drug crystallization was seen for the water in oil emulsion or micro-emulsion but was observed with the cyclodextrin formulation.
On addition to SPB buffer (6%v/v), the pH of the buffer decreased by: • 4 units for the control solution; • 3.5 units for the micro-emulsion formulation; • 1.4 units for the cyclodextrin formulation; and, • <0.1 units for the water in oil emulsion formulation.
Light scattering experiments showed that drug precipitation from the cyclodextrin solution was reduced compared with a control solution.
Summary of Characterisation Findings The characterisation experiment showed that for in vitro experiments, the proposed formulations do not readily precipitate out when compared to a control low pH formulation used in the prior art. As a result they show promise for in vivo applications.
TBI Experiment 2 - in Vivo Characterisation Formulation Preparation The formulations used include: 1. A complexed formulation using hydroxylpropyl-0-cyclodextrin as the complexing agent; 2. A micro-emulsion formulation; and, 3. A water in oil emulsion.
To investigate the tissue tolerance and pharmacokinetics of the proposed formulations, three formulations were prepared, all of which contained approximately 5%w/v ricobendazole, as follows: 17 • A water in oil emulsion was prepared by shaking 55% of an acidic ricobendazole solution with 42% ethyloleate and 3% emulsifiers.
• A micro-emulsion was prepared by mixing 75%v/v medium chain triglyceride with emulsifiers and 25% of an acidic solution of ricobendazole.
• A cyclodextrin formulation was prepared by mixing an acidic solution of ricobendazole with 20%w/v hydroxypropyl-p-cyclodextrin.
These formulations were equivalent to that used in Experiment 1 for the in vitro trial.
Control Samples The irritation and bioavailability of the three ricobendazole formulations were measured and compared against a positive control (a low pH solution (<2) and a negative control (a saline solution). The positive control formulations contained approximately 5%w/v ricobendazole. Vehicle control solutions were: a 0.3M HCI solution (positive control); the micro emulsion, water in oil emulsion; and cyclodextrin solution prepared with normal saline as the aqueous phase (negative control).
Animal Selection Five female sheep weighing 69.1± 3.4 kg in good health and with no signs of disease were used in the trials.
No study animal had pre-existing visible lesions on the injection site, nor had they received any injections to either side of the back during the previous six weeks.
Animals were housed within a test facility during the study.
The sheep received a tranquiliser by intravenous (IV) injection of Acezine (acepromazine, 0.2 mg/ kg). While under anesthetic, a jugular IV catheter (14 GA, 2 in, or 2.1 mm, 5.1 cm) was inserted and fixed for sampling of blood during the course of the experiment.
Formulation Administration Formulations were administered subcutaneously to each sheep by a veterinarian on one side of the back, each formulation including a ricobendazole dose of approximately 0.1 ml/kg.
Respective vehicle formulations (excluding ricobendazole) of approximately the same volumes were administered at the contralateral side of each sheep.
All injection sites were shaved before administration to allow easy observation of the injection site.
The formulations administered are summarised in Table 1 below. 18 Table 1 - Formulations administered in the Experiment Sheep Sheep A Sheep B Sheep C Sheep D Sheep E Tag No. 333 332 31 28 339 Body Weight (Kg) 66 70.5 66 74 69 Formulation Used Complexed Saline (Negative Control) LowpH solution (Positive Control) Water in oil emulsion Micro-emulsion Tissue Irritation Visual observation During the study visual observations were made regarding the reactions of the sheep to each injection along with reaction of the tissue at the injection sites.
Visual observations were done specifically to determine any signs of immediate post injection discomfort, any injection site swelling or redness and the reaction of the sheep on palpation of the injection site.
Skin Temperature An infrared non-touching thermometer was used to determine the skin temperature at the injection sites.
To verify tissue inflammatory reactions, measurements were taken of the: • Maximum skin temperature; • The time at which the maximum temperature was reached (peak time).
• The duration during which elevated skin temperatures were noted.
• The calculated total area under temperature-time curve above 34°C which was taken as a baseline skin temperature Creatine kinase (CK) level To determine if damage had occurred to superficial muscle tissue, blood samples were taken at time intervals of 0,1, 2, 4, 6,12,18, 24, 30, 36, 48 hours, then taken daily in the first week, and then by jugular vein puncture in the second week of the trial period. 19 To ensure blood samples remained stable, samples were immediately centrifuged at 3000rpm for 5 minutes as each blood sample was taken and the plasma transferred into Eppendorf tubes and kept at -20°C until analysis was completed.
Injection Site Histology After two weeks the injection sites were removed for histological examination by biopsy technique after sheep were given IV injection of Acezine (acepromazine, 0.2 mg/ kg) followed by local injection of 2-3ml 2% lignocaine.
Biopsy samples taken were 12mm in diameter including the epidermis, dermis and subcutis layers. Each biopsy sample specimen was placed in 10% formalin solution until histological examination was completed.
Pharmacokinetics The pharmacokinetics of ricobendazole and its main metabolite albendazole sulphone were measured using solid phase extraction (SPE) and analysis by high performance liquid chromatography.
Solid phase extraction procedure 1. Solid phase extraction (SPE) cartridges (Strata® C 18-E, 200 mg, 3 ml reservoir, Phenomenex, New Zealand) were conditioned by washing with 3 ml of methanol followed by 3 ml of water. 2. 1 ml aliquots of sheep plasma were spiked with 10pl internal standard (oxfendazole 50 |jg/ml) and vortexed for 1 minute. 3. Samples were diluted 1:1 with water, then loaded onto the conditioned SPE cartridges and washed with 0.5ml 40% methanol followed by 9ml water then dried by vacuum (20kPa) at ambient temperature for 5 minutes. 4. Compounds to be analysed were eluted with 2 ml methanol.
. Methanol was evaporated with a stream of nitrogen gas and the dried material was re-dissolved in 200 pi mobile phase. 6. Reconstituted samples were centrifuged and the supernatant was transferred into the glass autosampler vials for HPLC assay.
HPLC analysis of ricobendazole and albendazole sulphone The HPLC system (Shimadzu, Kyoto, Japan) comprised a LC 10-AT quaternary pump equipped with a SiMOAD auto-sampler, a SPD-10A variable wavelength detector and CTO-10ASVP column oven (30°C) all controlled by a computer using Class-VP 6.1 software.
Separation was carried out on a 4.6mm x 250mm column connected with a 4.6mm x 30mm pre-column (both C18 Prodigy, 5(i, Phenomenex®, NZ).
The calibration curve was linear over a concentration range of 10 to 1000ng/ml for ricobendazole (R2 > 0.999) and the main metabolite of ricobendazole, albendazole sulfone (R2 > 0.999).
Intra-day and inter-day precision and accuracy at the low, medium and high concentration for ricobendazole and albendazole sulphone, are listed in Table 2 below.
The extraction recoveries at these concentrations for the ricobendazole metabolite, albendazole sulfone were all over 96 % and the internal standard was 97.2 ± 4.2%.
Table 2. Intra-day and inter-day precision and accuracy of ricobendazole and albendazole sulfone Nominal conc. Cone, found Precision Accuracy (ng/ml) (mean) (ng/ml) (% CV) (% of nominal) Intra-day (n=5) 400 800 Inter-day (n=5) 400 800 a> o N CO T3 c ® -Q O O bn 19.7 ±1.1 403.8 ± 9.5 808.6 ± 35.7 .2 ±1.2 409.4 ±10.1 806.3 ± 17.1 .5 2.4 4.4 .9 2.5 2.1 98.3 ± 5.4 101.0 + 2.4 100.5 ±4.5 101.0 ±6.0 102.4 ±2.5 100.8 ±2.1 ® C a 3 cn _® o N CO TJ c <D -Q Intra-day (n=5) 20 400 800 Inter-day (n=5) 20 400 .4± 1.5 398.7 ± 20.0 798.8 ± 46.7 .6 ± 1.3 406.4 ± 9.4 7.4 5.0 5.9 6.4 2.3 102.0 ±4.1 99.7 ± 4.6 99.8 ±4.1 103.2 ±6.6 101.6 ±2.3 21 800 801.9 ±22.0 2.7 100.2 ±2.7 Pharmacokinetic Analysis Drug and metabolite information gathered from the experiments were analysed by software (GraphPad Prism, USA) based on the statistical moment theory.
The linear trapezoidal rule was used to calculate the area under the curve (AUC) and the area under the first moment curve (AUMC). The AUC and AUMC extrapolated beyond the last observed point C n was obtained from Cn/A, and Cn /A (tn+1/ A) respectively. A is the slope obtained from the regression of natural logarithm of concentration versus time in the terminal phase.
The mean residence time (MRT) was calculated as the ratio of AUMC to AUC.
The maximum concentration Cmax and the time when it occurred Tmax were observed data.
Relative bioavailability of different formulations compared to the positive control low pH solution was estimated by comparison of AUC for each formulation.
Results Irritation study Sign of pain upon injection Table 3 below records the animal response upon subcutaneous injection.
Table 3. Observed pain of the animals on injection Sheep Sheep A Sheep B Sheep C Sheep D Sheep E Formulation Used Complexed Saline (Negativ e Control) Low pH solution (Positive Control) Water in oil emulsion Micro-emulsion Formulation injection + - ++ - ± Vehicle injection - - ++ - - No sign of pain observed ± : Pain sign not significant +: Pain signs at the end of injection, movement continued for <10 seconds.
++: Showing pain immediately upon the injection and lasted for half minute.
Description of sign of pain response: Animal moved backward, the back stiffened. 22 Sheep C (the positive control) showed obvious signs of pain. A transient pain response was observed for sheep A when the complexed drug was administered.
No other pain responses were observed when remaining formulations and vehicles were administered to sheep B, D and E.
After administration, no animal was observed to exhibit signs of pain or discomfort during the two weeks subsequent to administration.
Swelling and Palpation Response Swelling at the injection site was only observed in sheep C (positive control) for 2 to 6 hours post drug administration. Swelling was most intensive after approximately 2 hours, with maximal edema dimension 6 X 6.3cm. Edema observed on the formulation side was slightly flatter (less inflamed) than the vehicle side.
Pain response to palpation of the injection site (see Table 4 below) was observed in sheep C (positive control) at both sites for between 1 Vi hours to 6 hours after injection. Pain response to palpation of the injection site was also observed for Sheep E (micro-emulsion) for approximately 2 hours post injection of the formulation side.
No animal exhibited signs of stress in the two weeks following administration of the formulations. Further, no signs of discomfort were observed in the general behavior of the test sheep.
Table 4 - Response of the sheep to Palpitation of the Injection Site Sheep Sheep A Sheep B Sheep C Sheep D Sheep E Formulation Used Complexed Saline (Negative Control) LowpH solution (Positive Control) Water in oil emulsion Micro-emulsion Formulation - - ++2 - + 1 Vehicle - - ++2 - - +1 Pain signs observed for approximately 2 hours post administration. ++2 Pain signs observed during the period of 1 Vz hours - 6 hours subsequent to administration.
Changes of skin temperature at the injection sites Results from the skin temperature analysis are shown below in Table 5.
Table 5 - Temperature Information Results 23 Formulation Used Water in oil emulsion Low pH solution (Positive Control) Micro-emulsion Saline (Negative Control) Complexed Sheep site F V F V V F L R V F Baseline Temperature CO 34 34 34 34 34 34 34 34 34 34 Peak Time (hr) 2 2 2 2 2 2 1 1 2 2 Peak Temp (°C) 37.2 37.3 38.3 38.3 37.4 37.5 37.1 37.3 37.6 37.7 Total area above normal (°Chr) 270 263 340 265 265 188 217 190 86 92 Peak Area (°C-hr) 123 129 225 164 91 99 28 38 48 Time over 34°C (hr) 120 122 125 123 64 64 23 21 23 F = Formulation including ricobendazole V = Formulation vehicle excluding ricobendazole L = Left side R= Right side All test sheep exhibited an increase in skin temperature at the injection sites and reached a temperature maximum after approximately two hours. The only exception to this was for the saline formulation (negative control), which reached maximum temperature after approximately 1 hour.
It is understood by the inventors that manipulation of catheterization may cause an increase in body temperature hence this may explain why the negative control Sheep B also exhibited a temperature rise.
Between Formulation and Vehicle No significant difference in skin temperature was noted between the two injection sites (formulation and vehicle) for Sheep B (negative control).
The formulation injection site for Sheep C (the positive control) reached a maximum temperature approximately 1°C higher than the vehicle site (hydrochloric acid (HCI) solution).
For the complexed and micro-emulsion formulations, there was a slightly higher skin temperature and peak area observed for the test formulation sites over the vehicle injection sites.
The temperature increase for the complexed site occurred at an early stage and returned to normal levels after approximately two days. The micro-emulsion formulation exhibited an approximate temperature maximum three days after administration. 24 Minimal differences in skin temperature were observed at the injection sites (formulation and vehicle) for the water in oil emulsion formulation.
Between Formulations Table 5 also shows the skin temperature versus time; the peak area over 34 °C (found to be the normal skin temperature); and the length of time that the temperature was elevated above the normal temperature.
As expected, across the five sheep, positive control Sheep C had the highest peak temperature (over 38°C); largest peak area; and longest duration of temperature increase (and hence peak area) lasting approximately 120 hours.
The overall reaction of each formulation was found to be rankable in the following order (highest temperature to lowest temperature): 1. Low pH solution - Positive Control (38.3°C) > 2. Complexed (37.6-37.7°C) > 3. Micro-emulsion (37.4-37.5°C) > 4. Water in Oil Emulsion (37.2-37.3°C) > or = . Saline - Negative Control (37.1-37.3°C).
Formulation and vehicle injection sites exhibited minimal increases in peak temperature and peak area (PAUC), with the increase usually lasting for 1 to 2 days (except for the emulsion formulation). Peak area proved to be a more reliable method to indicate the inflammatory response rather than the total area. Inflammation extent caused by formulation and vehicle injections ranked by peak area were found to be in the order (highest to lowest): 1. Low pH solution - positive control (225-164°Chr) > 2. Emulsion (123-129°C hr) > 3. Micro-emulsion (91-99°C hr) > 4. Complexed (38-48°C hr) > . Saline - Negative Control (25-28°C hr).
Plasma Creatine Kinase (CK) Level Plasma CK levels measured for each sheep during the first 48 hours after injection are shown in Figures 3 and 4.
The results show an increase in CK level for all sheep to differing extents, including the negative control sheep B. Generally, CK levels less than 500i.u. are not considered clinically significant and elevation measured in this study is likely to have resulted from: • CK rise caused by the manipulation of cannulation - there is a clear relation between the time gap between drug administration (first sampling) and cannulation; • CK level fluctuated when the animals were able to run freely and needed to be caught for sampling i.e. Sheep C, D and E were held during the first 48 hours and sheep A and B were released on the first day; and/or, • Assay error.
Biopsy Results No necroses or inflammatory reactions were observed for any test sheep at the biopsy site. Table 6 below shows the results for each formulation and vehicle.
Figures 5 and 6 also show the intersection of the skin at the injection sites including epidermis 10, dermis 11, panniculus muscle 12, subcutaneous fat 13 or adipose tissue for normal tissue (Figure 5) and the positive control Sheep 3 (Figure 6).
Histological Results Saline samples for Sheep B (negative control) (formulation and vehicle) showed no remarkable tissue damage.
Sheep C skin treated with low pH ricobendazole solution (positive control) showed mild to moderate multifocal coalescing inflammation of adipose tissue (steatites). This can be seen in Figure 6. The inflammation does not extend to the deep margin.
Note that the positive control vehicle (low pH) did not cause tissue damage as severe as the formulation.
No remarkable morphology change was noted in the samples for the micro-emulsion formulation (formulation and vehicle).
Minimal haemorrhage in the subcuticular fat region was observed for the water in oil emulsion.
Local haemorrhage in the hypodermis and pannicular fat was observed for the complexed formulation (formulation and vehicle). 26 Table 6 - Skin Tissue Pathology Sheep Side Histopathology Morphologic Index Sheep C-Positive control Right (V) Epidermis, dermis, panniculus muscle and adipose tissue present.
Focal haemorrhage in the subcuticular fat.
Otherwise unremarkable.
Unremarkable Left (F) Epidermis, dermis, panniculus muscle and adipose tissue present.
A mutifocal coalescing inflammatory cell infiltrate is present in the fibroblasts and juvenile blood vessels (granulation tissue) and saponification of fat. The inflammation does not extend to the deep margin.
Skin: Steatitis multifocal coalescing, chronic, mild to moderate. (Fig 3 right) Sheep B- Saline (Negative Control) Left Epidermis and dermis (including hypodermis). The tissue is unremarkable.
Unremarkable Right Epidermis and dermis (including hypodermis). The tissue is unremarkable.
Unremarkable Sheep A -Complexed Right (F) Epidermis and dermis (including hypodermis) present. Focal haemorrhage in the hypodermis and subcuticular fat. The section is otherwise unremarkable.
Unremarkable Left (V) Epidermis, dermis and pannicular fat. There is mutifocal locally extensive haemorrhage in the hypodermis and pannicular fat.
Unremarkable Sheep E- Micro-emulsion Right (F) Epidermis, dermis, panniculus muscle and adipose tissue present.
The section is unremarkable.
Unremarkable Left (V) Epidermis and dermis present. The tissue is unremarkable.
Unremarkable Sheep D-Water in Oil Emulsion Left (F) Epidermis, dermis, panniculus muscle and adipose tissue. Minimal multifocal haemorrhage in the subcuticular fat. Otherwise unremarkable.
Unremarkable Right (V) Epidermis, dermis, panniculus muscle and adipose tissue present.
Mild focal haemorrhage in the hypodermis and pannicular adipose tissue.
Otherwise unremarkable.
Unremarkable Pharmacokinetics Figures 7 and 8 show the measured blood plasma concentration of ricobendazole over time (Figure 7) and the ricobendazole metabolite, albendazole sulfone, blood plasma concentration over time (Figure 8) in sheep post administration of the ricobendazole containing formulations. 27 The formulations differed in the pharmacokinetic parameters as shown in Table 7 below. Table 7 - Pharmacokinetic Parameters Pharmacokinetic Parameters Ricobendazole Albendazole Sulfone Sheep C A D E C A D E Cmax (|jg/ml) 1.09 2.97 1.12 1.26 0.67 0.80 0.66 0.54 Tmax (hr) 9 4 24 12.0 9 4 24 12.0 k (hr"1) 0.074 0.153 0.089 0.076 0.025 0.154 0.107 0.128 11/2 (hr) g.3 4.5 7.8 9.08 28.2 4.5 6.5 .43 AUC o-oc (pg.day.mr1) 2g.03 56.51 45.57 32.38 17.61 23.29 .69 17.26 MRT (hr) 17.8 .3 32.5 23.2 24.7 21.4 37.0 28.2 Relative F (%) 1.00 1.94 1.55 1.11 1.00 1.32 1.45 0.98 Abbreviations Used: k is the elimination rate constant; t m is the half time; Cmax is the observed maximum plasma concentration; Tmax is the time at which Cmax occurred; AUC o-cc is the area under the concentration- time curve extrapolated to infinity; MRT is the mean residence time; Relative F is the relative bioavailability compared to the low pH solution.
It was found that the low pH solution (positive control) exhibited slow absorption with a plateau concentration of Ipg/ml between approximately 5 to 18 hours and a mean residual time of 17.8 hours.
The complexed formulation presented a rapid and (in the inventor's experience), a likely complete absorption, which resulted in the highest plasma ricobendazole concentration of 3pg/ml at T^x 4.5 hrs. The AUC is nearly double that observed for the positive control formulation.
The water in oil emulsion exhibited a sustained absorption and a longer mean residence time (32.5hr) than the positive control. Ricobendazole concentration remained at a level of approximately 1 pg/ml for approximately 30 hours and the AUC was higher than the positive control. 28 The micro-emulsion exhibited rapid absorption compared with the positive control but, in the inventor's opinion, absorption may be incomplete. The mean residence time is slightly longer than the positive control solution.
The above results imply that for all three test formulations, the anthelmintic delivery systems used increased the bioavailability of the ricobendazole over the positive control. When ranked in order of bioavailability increase, the order is (highest to lowest, amount / % increase over the positive control): 1. Complexed Formulation (3pg/ml, 94%) > 2. Water in Oil Emulsion (1 pg/ml for approximately 30 hours, 55%) > 3. Micro-emulsion (1 pg/ml and slightly higher MRT over the positive control, 15%) > 4. Positive Control.
Experiment 2 Summary All three formulations containing ricobendazole compound modified with various formulation approaches (complexed, micro-emulsion and water in oil emulsion) were found to improve tissue tolerance over existing formulations e.g. low pH when injected into sheep.
All associated formulation vehicles were well tolerated with no observation of pain upon injection, no change in histology in skin tissue at injection sites and minimal skin temperature rise.
All three formulations were found to increase bioavailability of ricobendazole relative to a positive control (a low pH solution).
The complexed formulation was found to be absorbed rapidly and completely in the sheep bloodstream. The water in oil emulsion was observed to act with a controlled release profile.
It should be appreciated by those skilled in the art that the above experiment shows that a complexed anthelmintic formulation appears to have a high potential to prevent drug precipitation.
In the case of the micro-emulsion formulation it is the inventors understanding that, when the formulation is mixed with the physiological fluid e.g. blood, a coarse emulsion forms, generating an emulsion layer that may avoid the burst release of low pH solution formulated in the micro-emulsion.
TCI Experiment 3 - In Vivo Characterisation Formulation Preparation 29 A complexed anthelmintic formulation ('formulation 1') was produced using the same method as that described in Experiments 1 and 2 above using ricobendazole as the anthelmintic, HCI acid, hydroxylpropyl-P-cyclodextrin as the complexing agent, benzyl alcohol and water.
A cyclodextrin vehicle formulation ('formulation 2') was produced using just cyclodextrin complexing agent and water (20% wt concentration).
A low pH control formulation ('formulation 3') was produced using ricobendazole as the anthelmintic in an HCI acid (pH ~2) solution without complexing agent.
A 'vehicle' formulation ('formulation 4') was produced using only 0.2M HCI acid.
Animals and Experimental Design 12 female adult sheep were used in Experiment 3. At the start of the trial, the sheep weighed 63.7 ± 2.2 kg on average and had no signs of disease. In addition, none of the sheep selected for experiment 3 had pre-existing visible lesions on the injection site, nor had they received any injections to either side of the back during the prior six weeks. Sheep were identified by ear tag and housed in a controlled test facility.
Sheep were randomly divided into two treatment groups (n = 6), being a control group given formulations 3 and 4 and a test formulation group given formulations 1 and 2.
Tests were conducted in three phases as shown below in Table 8 below.
Table 8: Experimental design for irritation and pharmacokinetic studies of ricobendazole formulations and vehicles after subcutaneous administration in sheep (Experiment 3) Phase Sheep Tag no.
Body weight (kg) Treatment Left side Right side A 389 63 Formulation 1 & 2 Formulation 1 Formulation 2 1 B 388 62 Formulation 1 & 2 Formulation 2 Formulation 1 *** C 390 391 64 61 Formulation 3 & 4 Formulation 3 Formulation 4 D 396 2 E 397 F 392 G 395 H 398 I 394 3 J 399 K 393 *** Sheep hurt after cannulation and caused bleeding from catheter overnight. The sheep was withdrawn from the trial.
Experimental protocol Jugular Vein Cannulation The day before injection, two areas (approximately 20x15cm) on each side of the back was shaved and marked using a permanent marker to identify the injection sites. A 14 gauge 5.1 cm long catheter was implanted in the jugular vein under ketamine/xylazine (80/8 mg/kg) anaesthesia for blood sampling. Animals were allowed to recover from surgery for 1 day before receiving test injections.
Drug administration Injection of the formulations were made subcutaneously at a dose of 0.1 ml/kg (equivalent to 5 mg/kg ricobendazole base) into the marked injection sites using a 19 gauge needle, and the corresponding vehicle was injected on the contralateral side of the sheep back at the same dose rate of ricobendazole. 63 Formulation Formu|ation 2 Formulation 1 61 Formulation Formulation 1 Formulation 2 65 Formulation Formu|ation 3 Formulation 4 62 For™lation Formulation 4 Formulation 3 67 Formulation Formulation 1 Formulation 2 gj Formulation Formulation 2 Formulation 1 64 Formulation Formulation 4 Formulation 3 66 Formulation Formulation 3 Formulation 4 3 & 4 31 Blood sampling 6 ml blood samples were withdrawn from the jugular catheter before injection and at 0.25, 0.5, 1,1.5, 2, 3, 4, 5, 6, 9,12,18, 24, 30, 36, 42 and 48 hours post dosing. This was completed to test drug and main metabolite levels for pharmacokinetic studies. 2 ml of additional blood was collected for measurement of creatine kinase concentrations at 0 (before drug administration), 2, 4, 6, 9, 12,18, 24 hours time points from formulation administration.
Blood samples obtained were stored in heparinized tubes; plasma was separated by centrifuged at 3000 rpm for 10 minutes and stored at -20 °C until analysed for drug concentration with a validated high performance liquid chromatography (HPLC) method. 0.5 ml plasma samples were stored in different tubes for analysis for creatine kinase concentration using standard analysis methods. Assay was performed within 2 days of collecting samples.
Injection site reactions - Observation of injection site reactions (a) Signs of pain on injection were recorded using the following scale: 0 = No signs of pain observed 1 = Pain signs not significant 2 = Pain signs at the end of injection, movement continued for <10 seconds. 3 = Showing pain immediately upon the injection and lasted for half minute. 4 = Showing severe pain immediately upon the injection and struggling. (b) Injection sites were observed including appearance of swelling and the size of edema; (c) Pain on palpation at the injection sites over the 48 hours and daily in the week. (d) Punch biopsy and tissue histological examinations. (e) Skin temperature change Skin temperature at the injection site was measured using an infrared non-touch thermometer before and at 0.5,1, 2, 4, 6, 9,12,18, 24, 30, 36 and 48 hours post injection. Two other sites were taken as reference points as shown on Figure 9 with the aim to eliminate the circadian changes in body temperature of the animals. Points on the skin for measurement of skin temperature are indicated by the letter X in Figure 9.
Skin temperature at the injection site was measured in Fahrenheit (°F).
Skin temperature changes at the injection site (7"ohange) were calculated as the difference relative to the two reference sites (Tref1, Tref2): 32 ^rise ~ 1'injectionsite (Trefl + ^\ef2 V ^ <T where a is the initial difference before treatment. All results were expressed as mean ± standard error (S.E.).
Punch Biopsy and Tissue Histology After seven days, sheep were anaesthetised and skin from the sheep at the injection sites was removed by punch biopsy (12mm diameter) and placed in 10% formalin. Once haemostasis at the biopsy site was assured, the wound was closed with 2/0 sutures and the animal allowed to recover. Histopathological examination under light microscopy was performed by an experienced Pathologist, who was unaware of the given treatment, at an independent laboratory. Microscopic changes in tissue were quantified by subjective evaluation of the following criteria on the scale of 0 (none) to 4 (greatest): 1. Perivascular dermatitis (inflammation in the superficial dermis). 2. Necrosis: irreversible cells death in tissue - muscle, subcutis, dermis - the most severe change. 3. Steatitis: inflammation of the fat. 4. Haemorrhage: the presence of blood in interstitial tissue outside the blood vessels resulted from escape of erythrocytes across intact vessels or from vascular rupture, often this is simply related to the collection of the biopsy, it can also be associated with the inflammation.
Pharmacokinetic study Quantification of Ricobendazole and Related Metabolites HPLC methods for quantification of ricobendazole and its main metabolites were completed as per known methods.
Pharmacokinetic Data Analysis Pharmacokinetic parameters were estimated using non-compartmental analysis based on statistical moment theory. The maximum concentration Cmax and the time when it occurred, Tmax. were observed directly. The linear trapezoidal rule was used to calculate area under the curve (AUC) and the area under the first moment curve (AUMC). AUC and AUMC extrapolated beyond the last data point Cn to infinite time were obtained from Cn/A and Cn /A (tn+1/A) respectively. A is the slope obtained from the regression of natural log concentration versus time in the terminal phase, over the last three data points. Elimination half-life (t1/2) was calculated as tV2 = 0.693/ X. Mean residence time (MRT) was calculated as the ratio of 33 AUMC to AUC. Relative bioavailability (F) of CD formulation was obtained by comparing AUC with that of the control formulation: AT1C j-isn/\ (Formulation) r (70) = A TTC A (Control) Statistical analysis Levels of statistical significance (P<0.05) were assessed using the ANOVA program to compare the data sets.
Experiment 3 Results and Discussion Irritation Studies - Visual Observations Table 9 below shows the visual observations made for sheep responses to subcutaneous injection of the test formulations and vehicles during 7 days of the experiment.
Table 9: Legend: 1: Formulation 1; 2: Formulation 2; 3: Formulation 3; 4: Formulation 4; M: muscle; D: dermis; S: subcutis). 34 Phase Sheep Treatment Pain on injection Histology Hemor- 1 A 389 1 3 1 2cm (1-6h) 1 1M 3 3 1 B 388 1 3 0 - 0 0 2 2 2 D 396 1 3 2 - 0 3D 0 1 2 E 397 1 3 3 ± (2-3h) 0 3M 1 2 3 H 398 1 3 0 - 0 0 0 2 3 I 394 1 3 1 - 0 0 0 1 1 A 389 1 4 0 - 0 0 3 2 1 B 388 1 4 0 - 0 0 1 1 2 D 396 1 4 0 - 0 0 0 1 2 E 397 1 4 0 - 1 0 2 2 3 H 398 1 4 0 - 0 0 1 1 3 I 394 1 4 0 . 1 0 0 1 1 C 391 2 3 0 - 1 0 2 1 2 F 392 2 3 0 - 1 0 1 1 2 G 395 2 3 1 2cm (1-6h) 2 0 1 0 3 J 399 2 3 2 3cm(1-9h) 2 1M 2 2 3 K 393 2 3 0 - 0 0 0 1 1 C 391 2 4 0 - 1 1S 2 1 2 F 392 2 4 0 - 1 0 2 1 2 G 395 2 4 1 2cm (1-4h) 2 0 1 1 3 J 399 2 4 0 - 2 0 2 1 3 K 393 2 4 0 _ 2 0 1 1 No presence of redness at the injection site was observed in sheep even if edema was observed. Further, no sheep showed visible pain signs to palpation on the injection site during the 7 days of the experiment.
Two of the six sheep exhibited a mild pain response after receiving formulation 1, and one sheep had slight swelling at the injection site. This swelling reduced and disappeared in a few hours. Injection of formulation 2 (complexing agent alone) did not cause pain on injection or a significant inflammation response. Both formulation 3 (low pH and ricobendazole ('RBZ')) and formulation 4 (low pH only) caused no or slight pain on injection in sheep.
Very slight swelling in the skin was found in two sheep shortly after injection of formulation 4 and one for the formulation 3.
Formulation 2 showed great tissue tolerance in sheep without evidence causing any pain on injection or significant inflammatory responses at the injection site.
Unexpectedly, the local anaesthetic effect of benzyl alcohol in formulation 1 was not obvious with the presence of hydroxylpropyl-P-cyclodextrin. This may be due to benzyl alcohol, acting as a hydrophobic compound, and forming an inclusion complex with cyclodextrin and reducing the local anaesthetic effect. In addition, addition of hydroxylpropyl-(3-cyclodextrin to formulations 1 and 2 increases the formulation osmolality and may also contribute to pain on injection. Sodium chloride equivalent (E) of ricobendazole low pH solution (formulation 3) is 1.0 (tonicity equal to a 1.0% NaCI solution), nearly isotonic, whereas formulation 1 is equivalent to a 1.5% NaCI solution, which is slightly hypertonic.
Histopathology of Injection Site Microscopic histology of the tissue of injection sites using the scoring system are listed in Table 2 above. Sheep biopsies treated with the formulation 3 and formulation 4 caused minimal or mild perivascular dermatitis and steatitis as shown in Figures 10A and 10B.
Minimal necrosis in muscle tissue was observed in the tissue treated with formulations 1 and 3 and in one of five animals (Figure 10C and 10D).
Biopsies treated with formulation 1 showed no perivascular dermatitis with one exception (minimal changes), and three of the six animals showed signs of steatitis in the biopsies. Minimal or mild necrosis was seen in three sheep in different tissue, but it did not extend to other tissues.
Contrary to formulation 1, no necrosis or morphological changes occurred in the tissue samples treated with formulation 2 (complexing agent alone). Only a few samples showed minimal steatistis and local haemorrhage.
Comparing the histology of the inflammation responses described above, ANOVA shows that there was no statistically significant difference between the formulations 1 and 3 (P>0.05) except for perivascular dermatitis (P<0.05) (see Table 10 below).
Table 10: Two-way analysis of variation (ANOVA) for histological changes in biopsies Factor Perivascular dermatitis Necrosis Steatitis Hemorrhage Formulation 1 vs 2 <0.05* >0.05 >0.05 >0.05 Formulation 3 vs 4 >0.05 >0.05 >0.05 >0.05 Histological measurement by light microscopy was completed at 7 days after formulation (1 to 4) administration. The timing of measurement was done to accurately reflect acute inflammation responses rather than the chronic reactions, which may be caused by ricobendazole precipitate.
Skin temperature at the injection sites 36 Local skin temperature at the injection sites and reference sites over a time period of 48 hours after subcutaneous injection of formulations 1 and 3 and vehicles (formulations 2 and 4) varied from 91 -96°F (see figures 11A and 11B). The temperature rise at the injection sites compared to the two reference sites is shown in Figure 11C.
Two minimum temperature measurements were observed at the 12 and 30 hour points over the 48 hours after injection between approximately 12am and 5am at night. A transient hypothermia 30 minutes after injection was observed in most of the animals, then temperature increased and became stable at a higher level. Two maximum elevation temperature Ternmax were observed, the time these occurred (Tmax) and the area under the temperature elevation-time curves (AUC) are compared in Table 11 below.
Table 11: Local skin temperature parameters in sheep after subcutaneous administration of formulation 1 (n=6) and formulation 3 (n=5) at a dose of 0.1 ml/kg (5 mg/kg ricobendazole) and the respective vehicles, formulations 2 and 4, at same dose (formulation and corresponding vehicle were injected on each side of sheep back).
Parameters Formulation 3 Formulation 4 Formulation 1 Formulation 2 Mean SE Mean SE Mean SE Mean SE AUC (hr°F) 68.9 .8 78.1 23.3 46.0 16.2 .2 9.4 Tmax 1 (hr) 9.4 3.8 22.8 4.4 8.6 4.5 6.7 4.7 Tem max 1 ( F) 2.5 0.4 3.1 0.8 2.3 0.6 2.4 0.6 ro 1.7 0.3 2.1 0.5 1.5 0.4 1.6 0.4 Tmax 2 (hr) 42 0.0 42.0 3.8 33.6 .4 24.0 1.7 Tem max 2 (°F) 2.9 0.3 2.1 0.5 1.4 0.3 1.7 0.3 (°C) 1.9 0.2 1.4 0.3 0.9 0.2 1.1 0.2 Three types of temperature-time curves were observed at the injection sites after injection of the formulations 1 and 3 and their vehicles, formulations 2 and 4 (Figure 11 A, 11B, 11C). This may suggest different mechanisms of injection site reactions including: 1) The temperature remained at a low, stable and close to normal level for cyclodextrin complexing agent alone (formulation 2) indicating minimal inflammation response in skin temperature. 2) A second hypothermia phenomenon was observed in both formulations before the hyperthermia at about 6-9 hours and 12 hours after administration of formulation 1 and formulation 3 respectively. It is thought this may be the result of a transient cut-off of blood vessels due the drug deposition. Loss of function of temperature regulation at the injection site due to the tissue damage may also be the cause or part of the cause. 3) Formulation 4 (HCI alone) caused a constant hyperthermia after administration with the maximum 2.1 °C maintained at 12-18 hours even at the night time and then returned to nearly normal after 48 hours. It has been reported that decrease in pH can stimulate nociceptors and induce pain and neurogenic inflammation. 37 Both the area under the temperature elevation-time curves (AUC) and maximum increase in skin temperature (Temmax) are ranked in the same order being: Formulation 4 > Formulation 3 > Formulation 1 > Formulation 2 Creatine Kinase Level Average concentration of plasma creatine kinase (CK) of sheep after receiving subcutaneous injection of formulations 1 and 3 along with the respective vehicles (formulations 2 and 4) are presented in Figure 12. Both sets of results were found to be associated with high inter-individual variability. A higher level of CK at the initial time (before injection) for both group and then a slight increase at 9 hours and then returned to for both formulations were observed. However, CK concentrations generally remained at the normal level in both groups.
CK is intracellular enzyme and primarily located in skeletal brain and heart muscle. Damage to these tissues caused the release of CK in to blood. After intramuscular injection of an irritating substance it was found the CmaX of CK appeared at 6 hours in cattle. In this study CK level in sheep after receiving a dose of formulations 1 and 3 (equivalent to 0.1 ml/kg) and the same dose of vehicle (formulations 2 and 4) simultaneously did not show significant increase in CK concentration over the 24 hours in any of the individual animal.
Pharmacokinetic study Following subcutaneous injection of formulation 1 and the formulation 3 at a dose of 5 mg/kg (ricobendazole) into sheep, the concentration-time curves of ricobendazole and its main metabolite, albendazole sulfone (ABZS02), were determined as shown in Figures 13 and 14 respectively. Figure 15 shows the mean values for the two formulations (istandard error). Non-com partmental pharmacokinetic parameters of ricobendazole are listed in Table 12 below.
Table 12: Non-com partmental pharmacokinetic parameters of ricobendazole after subcutaneous administration of formulation 1 (n=6) and formulation 3 (n=5) in sheep at a dose of 5 mg/kg (ricobendazole base). a) Individual data of formulation 1(n=6): 38 Kinetic variables A B D E H I Mean s.d.
CV(%) Cmax (MQ/ml) 2.80 3.74 2.31 2.94 3.90 1.95 2.9 0.77 26.2 Tmax (h) 6 4 .0 0.63 12.6 k( 1/h) 0.19 0.18 0.19 0.21 0.072 0.08 0.2 0.06 39.2 R-sq 3.66 3.93 3.62 3.38 9.61 8.58 .5 2.84 52.0 f-i/2 (h) AUCcMSh (Mg.h/ml) AUCo- -(Mg.h/ml) 0.86 43.82 43.91 0.92 62.09 62.37 0.99 42.3 42.4 0.86 55.57 55.65 0.95 76.73 80.75 0.91 40.7 42.1 0.9 53.5 54.5 0.05 14 15.3 .6 26.4 28.0 AUMC 662 1060 566.3 762.4 1216 593.2 810.2 267 33.1 MRT (h) .09 17.00 13.4 13.70 .07 14.1 14.7 1.3 9.0 b) Individual data of formulation 3 (n=5): Kinetic variables C G F J K Mean s.d.
CV(%) Cmax (pg/ml) 1.58 1.045 1.26 1.2 1.72 1.34 0.31 23.3 Tmax (h) 4 12 12 12 6 9.2 3.9 42.4 /c (1/h) 0.07 0.11 0.05 0.08 0.16 0.09 0.04 44.3 R-sq 0.91 0.97 0.95 0.92 0.94 0.94 0.02 2.6 U/2 (h) .17 6.09 12.97 8.85 4.22 8.46 3.43 40.5 AUQms (Mg.h/ml) 44.99 22.48 32.43 37.2 37.97 .01 8.32 23.8 AUCo--(Mg.h/ml) 48.55 22.93 .60 38.21 38.21 36.70 9.20 .0 AUMC 892.3 380 632.8 735.1 546.2 637.3 193.1 .3 MRT (h) 18.38 16.54 17.78 18.63 14.29 17.12 1.78 .4 Tmax. Cmax, and AUC0_-for formulation 3 were 9.2 ± 3.9 hours, 1.34 ± 0.31 |jg/ml, and 36.7 ± 9.2 |jg.hr/ml, respectively; while the corresponding data for formulation 1 were 5.0 ± 0.6 hours, 2.9 ± 0.8 pg/ml, and 53.5 ± 14.1 |jg.hr/ml. These results strongly suggest that cyclodextrin complexing agent improved both ricobendazole absorption rate and extent significantly (F<0.05).
It should be noted that the pharmacokinetic results obtained in this experiment such as AUC and Un are comparable with results reported in the literature. For example, one reference reports that after intravenous administration of ricobendazole at the same dose in sheep (n=6) AUC was 52.0 ± 8.0 |jg.hr/ml, which was nearly identical with the AUC of the test formulation used in this experiment. Thus, drug absorption of formulation 1 may be assumed to be complete. It is understood that this is because a higher portion of free drug dose is available for absorption in formulation 1 compared with formulation 3 which has no complexing agent.
The loss of plasma ricobendazole appears to follow first-order kinetics. The slope in the elimination phase appeared to have a significant difference in formulations 1 and 3.
Formulation 1 appeared to have a shorter half-life (5.5 ± 2.8 hours) and MRT (14.7 ± 1.3 hours) than formulation 3 (8.5 ± 3.4 hours and 17.1 ± 1.8 hours respectively). It is understood that this is primarily due to complete absorption of formulation 1 and by contrast, the slow release of drug precipitate at the injection site from formulation 3. 39 Table 13 below shows the statistical results indicating that incorporation of complexing agent in formulation 1 significantly improves drug absorption kinetic parameters.
Table 13: Comparison of pharmacokinetic parameters of RBZ containing formulations 1 and 3 after subcutaneous injection in sheep (*P<0.05, significant difference).
Kinetics parameters P-value Group ratio (CD solution /control) Cmax (MQ/ml) 0.002* (2.94+0.77/1,34±0.31) 2.2 Tmax (h) 0.028* (5.0±0.63/9.2±3.9) 0.5 /f (1/h) 0.103 (0.15±0.06/0.10 ±0.04) 1.6 f-l/2 (h) 0.147 (5.47±2.84/8.46 +3.43) 0.6 AUC(M8h(M9-h/ml) 0.030* (53.5±14/35.0±8.3) 1.5 AUCo--(|jg.hr/ml) 0.049* (54.5±15.3/36.7±9.2) 1.5 MRT (h) 0.030* (14.7±1.3/17.1±1.8) 0.8 Experiment 3 Summary Local irritation and bioavailability of a 5% ricobendazole injectable formulation at low pH with the presence of 20% cyclodextrin formulation 1, compared with the low pH solution alone (formulation 3) was investigated in sheep after subcutaneous administration at a dose of 5 mg/kg (0.1 ml/kg). The respective vehicles (20% cyclodextrin (formulation 2) and 0.2 M hydrochloric acid (formulation 4)) were also tested in the same animals for irritation assessment at the same dose.
It was found that formulation 1 containing cyclodextrin complex and ricobendazole significantly increased drug absorption. Compared with formulation 3, AUC and Cmax measurements were 1.6 and 2.2 times higher for formulation 1 containing cyclodextrin. Therefore, it is the inventors' understanding that formulation strategy to minimise precipitation is of importance for improvement of bioavailability and tissue tolerance (long term). This is partially because of inclusion formation with a complexing agent, and because of the inhibitive effect of complexing agent on anthelmintic precipitation at the injection site. Thus, using a combined approach of pH adjustment and complexation, drug absorption enhancement of at least 1.6 orders of magnitude is possible. One advantage of this is that finding is that a smaller dose could be administered to achieve the same efficacy. This in turn could significantly reduce the degree of local irritation.
The complexing agent used showed good tissue tolerance in sheep without evidence of causing any pain on injection or significant inflammatory responses at the injection site. This suggests complexing agents are a good injectable formulation carrier for poorly soluble drugs.
Aspects of the present invention have been described by way of example only and it should be appreciated that modifications and additions may be made thereto without departing from the scope thereof as defined in the appended claims. 40

Claims (32)

WHAT WE CLAIM IS:
1. An injectable formulation including at least one benzimidazole compound of the general formula: H which is complexed with a cyclodextrin compound selected from: (a) hydroxypropyl p-cyclodextrin compounds of the formula: cfbor ch2or " where R is CH2CHOHCH3 or H; or, (b) sulphabutyl ether p-cyclodextrin compounds with the formula: 41 Intellectual Property Office of N.Z. 31 JAN 2007 RECEIVED ch2or ch2or ch2or where R is (CH2)4S03Na or H; or, (c) a-cyclodextrin with six sugar units in the cyclodextrin ring; or, (d) y-cyclodextrin with eight sugar units in the cyclodextrin ring; and mixed with benzyl alcohol; characterised in that the formulation increases the solubility and/or dispersion properties of the benzimidazole compound.
The injectable formulation as claimed in claim 1 wherein the complexing compound is a p-cyclodextrin compound of the formula: or, 42 intellectual Property Office of N.Z. 3 1 JAN 2007 RECEIVED or an analogue or derivative thereof.
3. The injectable formulation as claimed in claim 1 wherein the complexing compound is hydroxypropyl-P-cyclodextrin with the formula: where R is CH2CHOHCH3 or H.
4. The injectable formulation as claimed in claim 1 wherein the complexed formulation includes approximately 20%w/v hydroxypropyl-P-cyclodextrin.
5. The injectable formulation as claimed in any one of claims 1 to 6 wherein the formulation releases the benzimidazole compound in a rapid manner.
6. An injectable formulation including at least one substituted or unsubstituted benzimidazole compound of the general formula: 43 intellectual Property Office of N.Z. 31 JAN 2007 RECEIVFD CO I H which is in the form of a micro-emulsion wherein the benzimidazole compound is characterised by having poor solubility and/or dispersion characteristics in an aqueous environment.
7. The injectable formulation as claimed in claim 6 wherein the micro-emulsion formulation includes at least one medium chain triglyceride compound and at least one emulsifier.
8. The injectable formulation as claimed in claim 6 or claim 7 wherein the micro-emulsion formulation includes 75% wt of at least one medium chain triglyceride compound and at least one emulsifier.
9. An injectable formulation including at least one substituted or unsubstituted benzimidazole compound of the general formula: I H which is in the form of a water in oil emulsion wherein the benzimidazole compound is characterised by having poor solubility and/or dispersion characteristics in an aqueous environment.
10. The injectable formulation as claimed in claim 9 wherein the water in oil emulsion formulation includes ethyloleate and at least one emulsifier.
11. The injectable formulation as claimed in either claim 9 or claim 10 wherein the water'in oil emulsion formulation includes 42% wt ethyloleate and 3% wt emulsifiers.
12. The injectable formulation as claimed in any one of claims 9 to 11 wherein the emulsion releases the benzimidazole compound in a slow manner.
13. The injectable formulation as claimed in any one of claims 6 to 12 wherein the formulations are characterised by their ability to retain benzimidazole compounds in solution within internal aqueous droplets of the systems and as a result, alter the solubility and/or dispersion properties of the benzimidazole compound.
14. The injectable formulation as claimed in any one of the above claims wherein the benzimidazole compound has a solubility in an aqueous 44 environment of less than 10mg Intellectual Property OfBoe of N Z. 3 1 JAN 2007 RECEIVED of benzimidazole per ml of aqueous solution.
15. The injectable formulation as claimed in any one of the above claims wherein the benzimidazole compound is characterised by having a bioavailability of less than approximately 50% absorption of the benzimidazole compound in the blood stream.
16. The injectable formulation as claimed in any one of the above claims wherein the aqueous environment is extra-cellular fluid.
17. The injectable formulation as claimed in any one of claims 1 to 16 wherein the H o Arv1 11 y—N— C—O—CH, h3c^S-k^^ H benzimidazole compound is albendazole: and combinations, analogues and derivatives thereof.
18. The injectable formulation as claimed in any one of claims 1 to 16 wherein the H ° ? rf*VYJ " 11 >—N— C—O—CH, h3C^s-L-^^ H benzimidazole compound is ricobendazole: and combinations, analogues and derivatives thereof.
19. The injectable formulation as claimed in any one of claims 1 to 16 wherein the benzimidazole compound is fenbendazole: and combinations, analogues and derivatives thereof.
20. The injectable formulation as claimed in any one of claims 1 to 16 wherein the Intellectual Property Office of N.Z. 31 JAN 2007 RECEIVED benzimidazole compound is oxfenbendazole: O H
21.
22.
23.
24.
25.
26. and combinations, analogues and derivatives thereof. The injectable formulation as claimed in any one of claims 1 to 16 wherein the benzimidazole compound is parbendazole: and combinations, analogues and derivatives thereof. The injectable formulation as claimed in any one of the above claims wherein the formulation is administered by means selected from: intravenous, subcutaneously, intramuscular. The injectable formulation as claimed in any one of the above claims wherein the benzimidazole compound is acidified with acid to a pH of 2 or less. The injectable formulation as claimed in claim 23 wherein the acid is hydrochloric acid. A method of treating a parasite infection in a non-human animal by administration of an injectable formulation as claimed in any one of claims 1 to 24. A method of increasing the solubility and/or dispersion characteristics of an benzimidazole compound of the general formula: in an aqueous environment by mixing the benzimidazole compound into a micro-emulsion. H Intellectual Property Office of N.Z. 46 31 JAN 2007
27. The method of claim 26 wherein the micro-emulsion includes at least one medium chain triglyceride compound and at least one emulsifier.
28. A method of increasing the solubility and/or dispersion characteristics of an benzimidazole compound of the general formula: I H in an aqueous environment by mixing the benzimidazole compound into a water in oil emulsion.
The method of claim 28 wherein the water in oil emulsion includes ethyloleate and at least one emulsifier.
30. A method of increasing the bioavailability of a benzimidazole compound of the general formula: H wherein the benzimidazole compound is characterised by having poor solubility and/or dispersion characteristics in an aqueous environment, via any one of the steps of: (a) complexing the benzimidazole compound with at least one cyclodextrin compound and mixing with benzyl alcohol; or,; (b) mixing the benzimidazole compound into a water in oil emulsion; or, (c) mixing the benzimidazole compound into a micro-emulsion.
31. Use of a formulation as claimed in any one of claims 1 to 24 in the manufacture of a medicament for the treatment of a parasite infection in an animal.
32. Use of a formulation as claimed in any one of claims 1 to 24 in the manufacture of a medicament to increase the solubility and/or dispersion of an benzimidazole compound wherein the benzimidazole compound is characterised by having poor solubility and/or 47 Intellectual Property Office of N.zT 3 I JAN 2007 RECEI v e d dispersion characteristics in an aqueous environment. Bomac Research Limited by their Attorneys JAMES & WELLS 48 Intellectual Property Office of N.2. 31 JAN 2007 RECEIVED
NZ534939A 2004-08-26 2004-08-26 Injectable formulation comprising an anthelmintic compound with complexing compound for improved solubility NZ534939A (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
NZ534939A NZ534939A (en) 2004-08-26 2004-08-26 Injectable formulation comprising an anthelmintic compound with complexing compound for improved solubility
PCT/NZ2005/000225 WO2006022562A1 (en) 2004-08-26 2005-08-26 Improved chemical delivery formulations

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
NZ534939A NZ534939A (en) 2004-08-26 2004-08-26 Injectable formulation comprising an anthelmintic compound with complexing compound for improved solubility

Publications (1)

Publication Number Publication Date
NZ534939A true NZ534939A (en) 2007-04-27

Family

ID=35967711

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ534939A NZ534939A (en) 2004-08-26 2004-08-26 Injectable formulation comprising an anthelmintic compound with complexing compound for improved solubility

Country Status (2)

Country Link
NZ (1) NZ534939A (en)
WO (1) WO2006022562A1 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102004011512B4 (en) 2004-03-08 2022-01-13 Boehringer Ingelheim Vetmedica Gmbh Pharmaceutical preparation containing pimobendan
EP1579862A1 (en) 2004-03-25 2005-09-28 Boehringer Ingelheim Vetmedica Gmbh Use of PDE III inhibitors for the reduction of heart size in mammals suffering from heart failure
US8980894B2 (en) 2004-03-25 2015-03-17 Boehringer Ingelheim Vetmedica Gmbh Use of PDE III inhibitors for the treatment of asymptomatic (occult) heart failure
EP1920785A1 (en) 2006-11-07 2008-05-14 Boehringer Ingelheim Vetmedica Gmbh Liquid preparation comprising a complex of pimobendan and cyclodextrin
BRPI0921868A2 (en) 2008-11-25 2015-12-29 Boehringer Ingelheim Vetmed phosphodiesterase type iii (pde iii) inhibitors or ca2 + sensitizing agents for the treatment of hypertrophic cardiomyopathy
US10398705B2 (en) 2012-03-15 2019-09-03 Boehringer Ingelheim Vetmedica Gmbh Pharmaceutical tablet formulation for the veterinary medical sector, method of production and use thereof
WO2015007760A1 (en) 2013-07-19 2015-01-22 Boehringer Ingelheim Vetmedica Gmbh Preserved etherified cyclodextrin derivatives containing liquid aqueous pharmaceutical composition
CN110721164A (en) 2013-12-04 2020-01-24 勃林格殷格翰动物保健有限公司 Improved pharmaceutical composition of pimobendan
CN104274403B (en) * 2014-10-14 2017-05-31 成都乾坤动物药业有限公司 A kind of Fenbendazole emulsion
WO2016157064A1 (en) 2015-03-30 2016-10-06 Deva Holding Anonim Sirketi Stable ricobendazole formulations
WO2017097855A1 (en) * 2015-12-08 2017-06-15 Verano Ilac Sanayi Ticaret Anonim Sirketi An injectable composition of ricobendazole
US10537570B2 (en) 2016-04-06 2020-01-21 Boehringer Ingelheim Vetmedica Gmbh Use of pimobendan for the reduction of heart size and/or the delay of onset of clinical symptoms in patients with asymptomatic heart failure due to mitral valve disease
BR102020021181A2 (en) 2020-10-16 2022-04-26 Ipanema Industria De Produtos Veterinarios Ltda Microsuspension against parasites and method for obtaining it

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0525307T3 (en) * 1991-07-23 1996-04-01 American Cyanamid Co Stable preparations for parenteral administration and their use
DE19613972A1 (en) * 1996-04-09 1997-10-16 Bayer Ag Injection formulations of avermectins and milbemycins based on castor oil
ATE249206T1 (en) * 1997-12-03 2003-09-15 Merck & Co Inc LONG-ACTING, INJECTABLE FORMULATIONS CONTAINING CASCIN OIL
CN1304727A (en) * 2000-10-20 2001-07-25 王玉万 Injection containing evericin or ivermectin and using benzyl benzoate or nitrone as co-solvent

Also Published As

Publication number Publication date
WO2006022562A1 (en) 2006-03-02

Similar Documents

Publication Publication Date Title
WO2006022562A1 (en) Improved chemical delivery formulations
US10213443B2 (en) Tetracycline topical formulations, preparation and uses thereof in treating an ocular condition
JP5709826B2 (en) Therapeutic composition
Zhang et al. Precision-guided long-acting analgesia by Gel-immobilized bupivacaine-loaded microsphere
US20130116271A1 (en) Tacrolimus-containing oil-in-water type creamy composition
JP3331414B2 (en) Uses of dibutyl adipate and isopropyl myristate in topical or transdermal products
CA2880347C (en) Injectable compositions comprising letrozole or anastrozole
Huang et al. A novel drug delivery carrier comprised of nimodipine drug solution and a nanoemulsion: preparation, characterization, in vitro, and in vivo studies
Salau et al. Enhancement of transdermal permeation of cannabinoids and their pharmacodynamic evaluation in rats
Niu et al. Hyaluronic acid micelles for promoting the skin permeation and deposition of curcumin
US20210379083A1 (en) Pharmaceutical composition and use
Wang et al. An absorbable local anesthetic matrix provides several days of functional sciatic nerve blockade
Khan et al. Formulation development of pharmaceutical nanoemulgel for transdermal delivery of feboxostat: Physical characterization and in vivo evaluation
CN116669717A (en) Long-acting in-situ forming/gelling composition
JP6382215B2 (en) Gel composition
CN114144200A (en) Sustained release local anesthetic hydrogel compositions
Srivastava et al. Preparation and Evaluation of Econazole Nitrate Containing Film-Forming Gel
Padaraju et al. Microemulsions, nanoemulsions and emulgels as carriers for antifungal antibiotics
WO2023016583A1 (en) Ruxolitinib composition and use thereof
US20200289476A1 (en) Liquid formulations of riluzole for oral and intravenous use
WO2023172216A1 (en) Hydrocortisone and pramoxine topical formulations having enhanced in-vitro release
Singh et al. Formulation and Evaluation of Emulgel Containing Diclofenac Sodium
Hespeler et al. Novel delivery system smartPearls–efficient delivery system for antioxidants in anti-pollution
Deadman Biopharmaceutical studies of slow release, subcutaneous polymeric drug delivery systems
Singhavi et al. Preparation and in-vitro/in-vivo Characterization of Transdermal Amphiphilogel Loaded with

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)
ASS Change of ownership

Owner name: BAYER NEW ZEALAND LIMITED, NZ

Free format text: OLD OWNER(S): BOMAC RESEARCH LIMITED

RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 7 YEARS UNTIL 26 AUG 2025 BY JAMES + WELLS

Effective date: 20140906

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 26 AUG 2018 BY JAMES + WELLS

Effective date: 20140906

ASS Change of ownership

Owner name: ELANCO NEW ZEALAND SIMPSON GRIERSON, NZ

Effective date: 20210707